Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype
- 1 October 2014
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy Methods
- Vol. 25 (5), 277-287
- https://doi.org/10.1089/hgtb.2014.004
Abstract
Advances in genetic engineering have made it possible to generate human T-cell products that carry desired functionalities, such as the ability to recognize cancer cells. The currently used strategies for the generation of gene-modified T-cell products lead to highly differentiated cells within the infusion product, and on the basis of data obtained in preclinical models, this is likely to impact the efficacy of these products. We set out to develop a good manufacturing practice (GMP) protocol that yields T-cell receptor (TCR) gene-modified T-cells with more favorable properties for clinical application. Here, we show the robust clinical-scale production of human peripheral blood T-cells with an early memory phenotype that express a MART-1-specific TCR. By combining selection and stimulation using anti-CD3/CD28 beads for retroviral transduction, followed by expansion in the presence of IL-7 and IL-15, production of a well-defined clinical-scale TCR gene-modified T-cell product could be achieved. A major fraction of the T-cells generated in this fashion were shown to coexpress CD62L and CD45RA, and express CD27 and CD28, indicating a central memory or memory stemlike phenotype. Furthermore, these cells produced IFNγ, TNFα, and IL-2 and displayed cytolytic activity against target cells expressing the relevant antigen. The T-cell products manufactured by this robust and validated GMP production process are now undergoing testing in a phase I/IIa clinical trial in HLA-A*02:01 MART-1-positive advanced stage melanoma patients. To our knowledge, this is the first clinical trial protocol in which the combination of IL-7 and IL-15 has been applied for the generation of gene-modified T-cell products.Keywords
This publication has 65 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- A human memory T cell subset with stem cell–like propertiesNature Medicine, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in HumansTransplantation and Cellular Therapy, 2010
- Adoptively transferred effector cells derived from naïve rather than central memory CD8 + T cells mediate superior antitumor immunityProceedings of the National Academy of Sciences of the United States of America, 2009
- Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania majorNature Medicine, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- CD8+ T‐cell memory in tumor immunology and immunotherapyImmunological Reviews, 2006
- Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vectorNature Biotechnology, 2004
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999